ENOV (Enovis) GF Value : $69.74 (As of Apr. 04, 2025)

View and export this data going back to 2008. Start your Free Trial

What is Enovis GF Value?

As of today (2025-04-04), Enovis's share price is $33.79. Enovis's GF Value is $69.74. Therefore, Enovis's Price-to-GF-Value for today is 0.48. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Enovis is Possible Value Trap, Think Twice.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Enovis (NYSE:ENOV) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Enovis's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	33.79	/	69.74
	=	0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enovis GF Value Related Terms

Thank you for viewing the detailed overview of Enovis's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Enovis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Enovis Corp (NYSE:ENOV) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

0I1B:UK C520:Germany

Address

2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808

Website

https://www.enovis.com

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Executives

John Kleckner	officer: Principal Accounting Officer	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben)	officer: SVP, Chief Financial Officer	2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota	director	8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall	director
Brady Shirley	officer: EVP, Colfax, Pres. & CEO, DJO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang	officer: SVP, Chief HR Officer	C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy	officer: SVP, General Counsel	P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor	officer: SVP??Strategy & Business Deve.	DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola	director, officer: President & CEO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix	officer: SVP, Chief Financial Officer	2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz	director	1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor	director	3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda	officer: ESAB President and SVP, Colfax	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts	officer: Controller, PAO	100 MATSONFORD ROAD, RADNOR PA 19087